How should speckle‑tracking echocardiography and global longitudinal strain be incorporated into routine transthoracic studies to detect subclinical cardiomyopathy and guide early initiation of cardioprotective therapy?

Incorporating Speckle-Tracking Echocardiography and Global Longitudinal Strain into Routine Practice

Global longitudinal strain (GLS) assessed by speckle-tracking echocardiography should be routinely measured in all patients at risk for cardiotoxicity, with a relative reduction >15% from baseline or an absolute GLS less negative than -16% triggering initiation of cardioprotective therapy, even when ejection fraction remains normal. 1

Why GLS is Superior to LVEF for Early Detection

GLS detects subclinical myocardial injury before LVEF declines, making it the most sensitive and specific measurement for early cardiotoxicity detection. 1 Traditional LVEF assessment has critical limitations:

• LVEF variability is too high (12-15%) to reliably detect the 10% drops used to define cardiotoxicity 2
• LVEF changes occur late, often months after irreversible myocardial damage has occurred 3
• GLS has superior reproducibility (5.5-9.5% variability) compared to LVEF 2
• GLS reflects longitudinal subendocardial fiber function, which is damaged earliest in cardiotoxicity 1, 4

Specific Thresholds for Clinical Action

Normal Reference Values

• Normal GLS: approximately -20% (range -18% to -22%) 5
• Lower limit of normal: -16% (values less negative than -16% are abnormal) 5
• Mild depression: < -16% 4
• Severe reduction: < -10% 4

Actionable Changes During Monitoring

The American Society of Echocardiography and European Association of Cardiovascular Imaging consensus provides clear cutoffs: 1

• GLS reduction <8% from baseline: Not clinically meaningful 1
• GLS reduction >15% from baseline: Very likely abnormal and requires intervention 1
• Intermediate reductions (8-15%): Increase monitoring frequency and consider early cardioprotective therapy 3

Practical Implementation Algorithm

Baseline Assessment (Before Chemotherapy)

1. Obtain baseline GLS using 2D speckle-tracking from three apical views (four-chamber, two-chamber, three-chamber) 5
2. Measure baseline LVEF using biplane Simpson's method or 3D echocardiography 2
3. Document vendor and software version to ensure consistency in serial measurements 5
4. Optimize image quality and frame rate to minimize measurement variability 5

Serial Monitoring Protocol

For anthracycline-based chemotherapy: 2

• Measure GLS at cumulative doses of 100-200 mg/m² (early changes detectable) 2
• Continue monitoring at 200 mg/m² (≥7% risk of LVSD), 400 mg/m² (≥16% risk), and 500 mg/m² (≥20% risk) 2

For trastuzumab or other HER2-targeted therapy: 3

• Measure GLS within 3 months of initiation 3
• GLS <-19% predicts subsequent cardiotoxicity and warrants closer monitoring 3

When to Initiate Cardioprotective Therapy

Start ACE inhibitors or beta-blockers when: 1, 3

• GLS shows >15% relative reduction from baseline (e.g., from -20% to -17% or worse) 1
• Absolute GLS becomes less negative than -16% 5
• These changes occur even with preserved LVEF 1, 3

This approach provides a window of opportunity to prevent irreversible cardiac dysfunction before LVEF declines. 2

Technical Considerations to Avoid Pitfalls

Measurement Standardization

• Use the same ultrasound equipment and software for all serial studies 5
• Average GLS from all three apical views with timing reference at aortic valve closure 5
• Exclude calculations when >2 segments have poor tracking in any single view 5
• Use mid-wall measurements rather than endocardial strain 5

Vendor Variability

Inter-vendor differences remain significant, so absolute values cannot be universally applied across different platforms. 5 However, relative changes within the same patient using the same equipment are reliable for detecting cardiotoxicity. 2, 5

Population-Specific Adjustments

• Women have slightly more negative GLS than men 5
• GLS decreases with age, requiring age-adjusted interpretation 5
• Values are not applicable to patients receiving inotropic support or mechanical circulatory support 4

Complementary Role of 3D Strain

3D speckle-tracking offers additional prognostic value beyond 2D GLS: 6

• 3D global radial strain (GRS) and 3D global circumferential strain (GCS) predict cardiotoxicity earlier than 2D parameters 6
• Optimal cutoffs: 3D GCS -34.2% and 3D GRS -34.4% 6
• 3D strain changes precede cardiotoxicity diagnosis by 23-45 days 6

However, 2D GLS remains the most validated and feasible parameter for routine clinical use. 2

Regional Strain Patterns

Regional longitudinal strain analysis identifies specific cardiomyopathy patterns: 1, 4

• Infiltrative cardiomyopathies (amyloidosis, eosinophilic): Prominent reduction in basal LV segments 4
• Hypertrophic cardiomyopathy: More generalized GLS reduction 4
• Chemotherapy-induced damage: Often affects interventricular septum preferentially 1

Integration with Biomarkers

Combining GLS with troponin and BNP increases sensitivity for early cardiotoxicity detection. 2 When both GLS and biomarkers are abnormal, the predictive value for subsequent cardiac dysfunction is highest. 2

Evidence Strength and Limitations

The 2019 European Myeloma Network/Italian Society of Arterial Hypertension consensus specifically endorses GLS as the most sensitive technique for early cardiotoxicity detection. 1 The 2020 ESMO consensus confirms that GLS facilitates early detection of subclinical dysfunction and may identify a therapeutic window before LVEF declines. 2

Critical caveat: While GLS consistently detects early myocardial changes, the predictive value for forecasting subsequent clinical cardiotoxicity requires further validation in prospective trials. 7 Nevertheless, the preponderance of evidence supports its clinical adoption given the superior sensitivity over LVEF and the potential to prevent irreversible cardiac damage. 1, 3, 2, 8